Research spotlight: Novel regimens demonstrate efficacy in colorectal cancer

March is Colorectal Cancer Awareness Month.

The campaign is intended to educate the public about risk factors of the disease — the third leading cause of cancer death in the United States — and the importance of screening.

Doctor holding blue ribbon. — *Source: Adobe Stock.*

In conjunction with this observance, Healio provides the following updates related to colorectal cancer treatment and detection that may be relevant to your practice.

A three-drug combination demonstrated activity for patients with microsatellite-stable, BRAF V600E-positive metastatic colorectal cancer. The regimen — which consisted of encorafenib (Braftovi, Pfizer), cetuximab (Erbitux, Eli Lilly) and nivolumab (Opdivo, Bristol Myers Squibb) — also appeared well-tolerated. Read more.
The combination of cabozantinib (Cabometyx, Exelixis) and durvalumab (Imfinzi, AstraZeneca) appeared safe and demonstrated efficacy among a small cohort of patients with advanced mismatch repair-proficient/microsatellite-stable colorectal cancer. Read more.
The FDA approved cetuximab (Erbitux, Eli Lilly) in combination with encorafenib (Braftovi, Pfizer) for treatment of certain patients with colorectal cancer. The indication applies to use of the agents by adults with BRAF V600E mutation-positive metastatic disease detected by an FDA-approved test who received prior therapy. Read more.
First-line nivolumab (Opdivo, Bristol Myers Squibb) plus standard of care chemotherapy failed to prolong 1-year PFS among patients with metastatic colorectal cancer. Read more.
Sotorasib (Lumakras, Amgen) demonstrated antitumor activity among patients with heavily pretreated advanced KRAS G12C-mutated colorectal cancer. Read more.
Younger and older patients with metastatic colorectal cancer had similar survival outcomes despite differences in fitness levels and treatment intensity. Read more.
Robotic-assisted surgery significantly improved outcomes compared with laparoscopic surgery among patients with middle and low rectal cancer. Read more.
Individuals aged between 20 and 39 years had the greatest burden of distant early-onset colorectal adenocarcinoma. Read more.
Consumption of unprocessed red or processed meat did not impact risk for colon cancer recurrence or mortality. Read more.
Weight loss during the first 3 months of systemic therapy for metastatic colorectal cancer coincided with significantly shorter OS compared with stable or increasing weight. Read more.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Coverage

Read more

Research spotlight: Novel regimens demonstrate efficacy in colorectal cancer

Related Content